Prostate Cancer Risk: Overview of the Disease, Predictive Factors, and Potential Targets for Risk ReductionANDRIOLE, Gerald L.Urology (Ridgewood, NJ). 2009, Vol 73, Num 5A, issn 0090-4295, 45 p., SUPSerial Issue

Cost-Effectiveness of Prostate Specific Antigen Screening in the United States: Extrapolating From the European Study of Screening for Prostate CancerSHTEYNSHLYUGER, Alex; ANDRIOLE, Gerald L.The Journal of urology. 2011, Vol 185, Num 3, pp 828-832, issn 0022-5347, 5 p.Article

Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in thetreatment of benign prostatic hyperplasiaANDRIOLE, Gerald L; KIRBY, Roger.European urology. 2003, Vol 44, Num 1, pp 82-88, issn 0302-2838, 7 p.Article

Prostate cancer chemoprevention with 5α-reductase inhibitorsNEPPLE, Kenneth G; ANDRIOLE, Gerald L.Urologic oncology. 2012, Vol 30, Num 5, pp 553-554, issn 1078-1439, 2 p.Article

Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5α-reductase inhibitor dutasterideANDRIOLE, Gerald L; MARBERGERT, Michael; ROEHRBORN, Claus G et al.The Journal of urology. 2006, Vol 175, Num 5, pp 1657-1662, issn 0022-5347, 6 p.Article

Critical Appraisal of Prostate-specific Antigen in Prostate Cancer Screening: 20 Years LaterPIENTA, Kenneth J.Urology (Ridgewood, NJ). 2009, Vol 73, Num 5A, pp 11-20, issn 0090-4295, 10 p., SUPArticle

Risk of Developing Prostate Cancer in the Future: Overview of Prognostic BiomarkersFLESHNER, Neil E; LAWRENTSCHUK, Nathan.Urology (Ridgewood, NJ). 2009, Vol 73, Num 5A, pp 21-27, issn 0090-4295, 7 p., SUPArticle

Understanding the Epidemiology, Natural History, and Key Pathways Involved in Prostate CancerCRAWFORD, E. David.Urology (Ridgewood, NJ). 2009, Vol 73, Num 5A, pp 4-10, issn 0090-4295, 7 p., SUPArticle

Prevention of benign prostatic hyperplasia diseaseMARKS, Leonard S; ROEHRBORN, Claus G; ANDRIOLE, Gerald L et al.The Journal of urology. 2006, Vol 176, Num 4, pp 1299-1306, issn 0022-5347, 8 p., 1Article

Application of a fixed retractor system to facilitate laparoscopic radical prostatectomyLANDMAN, Jaime; VENKATESH, Ramakrishna; VANLANGENDONCK, Richard et al.The Journal of urology. 2004, Vol 171, Num 2, pp 783-785, issn 0022-5347, 3 p., 1Article

Overdiagnosis of Prostate CancerSANDHU, Gurdarshan S; ANDRIOLE, Gerald L.Journal of the National Cancer Institute. Monographs. 2012, Vol 45, pp 146-151, issn 1052-6773, 6 p.Conference Paper

Reduction in the Risk of Prostate Cancer: Future Directions After the Prostate Cancer Prevention Trial. CommentaryCRAWFORD, E. David; ANDRIOLE, Gerald L; MARBERGER, Michael et al.Urology (Ridgewood, NJ). 2010, Vol 75, Num 3, pp 502-510, issn 0090-4295, 9 p.Article

Current Prostate Cancer Treatments: Effect on Quality of LifeGOMELLA, Leonard G; JOHANNES, James; TRABULSI, Edouard J et al.Urology (Ridgewood, NJ). 2009, Vol 73, Num 5A, pp 28-35, issn 0090-4295, 8 p., SUPArticle

Alcohol Intake Increases High-grade Prostate Cancer Risk Among Men Taking Dutasteride in the REDUCE TrialFOWKE, Jay H; HOWARD, Lauren; ANDRIOLE, Gerald L et al.European urology. 2014, Vol 66, Num 6, pp 1133-1138, issn 0302-2838, 6 p.Article

Relating biopsy and clinical variables to radical prostatectomy findings: Can insignificant and advanced prostate cancer be predicted in a screening population?ANAST, Jason W; ANDRIOLE, Gerald L; BISMAR, Tarek A et al.Urology (Ridgewood, NJ). 2004, Vol 64, Num 3, pp 544-550, issn 0090-4295, 7 p.Article

Modeling and Analysis of Gleason Score 8-10 Prostate Cancers in the REDUCE StudyANDRIOLE, Gerald L; BOSTWICK, David G; CASTRO, Ramiro et al.Urology (Ridgewood, NJ). 2014, Vol 84, Num 2, pp 393-399, issn 0090-4295, 7 p.Article

The utility of prostate-specific antigen in the management of advanced prostate cancerCRAWFORD, E. David; BENNETT, Charles L; ANDRIOLE, Gerald L et al.BJU international (Papier). 2013, Vol 112, Num 5, pp 548-560, issn 1464-4096, 13 p.Article

Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE studyMARBERGER, Michael; FREEDLAND, Stephen J; ANDRIOLE, Gerald L et al.BJU international (Papier). 2012, Vol 109, Num 8, pp 1162-1169, issn 1464-4096, 8 p.Article

Dutasteride Improves Outcomes of Benign Prostatic Hyperplasia When Evaluated for Prostate Cancer Risk Reduction: Secondary Analysis of the REduction by Dutasteride of Prostate Cancer Events (REDUCE) TrialROEHRBORN, Claus G; CURTIS NICKEL, J; ANDRIOLE, Gerald L et al.Urology (Ridgewood, NJ). 2011, Vol 78, Num 3, pp 641-646, issn 0090-4295, 6 p.Article

Identification of a new prostate cancer susceptibility locus on chromosome 8q24YEAGER, Meredith; CHATTERJEE, Nilanjan; KAI YU et al.Nature genetics. 2009, Vol 41, Num 10, pp 1055-1057, issn 1061-4036, 3 p.Article

Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failureRADWAN, Mohamed H; YAN YAN; LULY, Jason R et al.Urology (Ridgewood, NJ). 2007, Vol 69, Num 6, pp 1121-1127, issn 0090-4295, 7 p.Article

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaMCCONNELL, John D; ROEHRBORN, Claus G; CRAWFORD, E. David et al.The New England journal of medicine. 2003, Vol 349, Num 25, pp 2387-2398, issn 0028-4793, 12 p.Article

Relationship of demographic and clinical factors to free and total prostate-specific antigenGELMANN, Edward P; CHIA, David; LEVIN, David L et al.Urology (Ridgewood, NJ). 2001, Vol 58, Num 4, pp 561-566, issn 0090-4295Article

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening TrialPROROK, Philip C; ANDRIOLE, Gerald L; HAYES, Richard B et al.Controlled clinical trials. 2000, Vol 21, Num 6, pp 273S-309S, issn 0197-2456, SUPArticle

Urological Symptoms in a Subset of Patients with Urological Chronic Pelvic Pain Syndrome and a Polysymptomatic, Polysyndromic Pattern of PresentationLAI, H. Henry; NORTH, Carol S; ANDRIOLE, Gerald L et al.The Journal of urology. 2014, Vol 191, Num 6, pp 1802-1807, issn 0022-5347, 6 p.Article